Novo Nordisk A/S (NVO) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Bagsvaerd, Denmark. 現CEOは Maziar Mike Doustdar.
NVO を有する IPO日 1981-04-30, 77,406 名の正社員, に上場 New York Stock Exchange, 時価総額 $174.74B.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 that researches, develops, manufactures, and distributes medications globally across Europe, the Middle East, Africa, China, and North America. The company operates through two primary segments: Diabetes and Obesity Care, which offers treatments for diabetes, obesity, and cardiovascular conditions, and Rare Disease, which focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Beyond pharmaceutical products, Novo Nordisk provides delivery devices such as insulin pens and growth hormone pens, as well as digital health solutions including smart insulin pens and dose guidance applications. The company has established strategic collaborations with UNICEF on childhood obesity initiatives and with Valo Health to develop cardiometabolic therapies.
